- Conditions
- Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Leukemia, Lymphoma, Graft-versus-host Disease
- Interventions
- Cord Blood Units, Total Body Irradiation, Cyclophosphamide, Fludarabine, Clofarabine, Busulfan, Thiotepa, Tacrolimus, Mycophenolate Mofetil, Cyclosporine
- Biological · Radiation · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 26 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 56
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- Gemcitabine, Oxaliplatin, Dexamethasone, Floxuridine (FUDR), Implanted Medical Device
- Drug · Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 10
- States / cities
- Bethesda, Maryland • St Louis, Missouri • Basking Ridge, New Jersey + 7 more
- Conditions
- Lymphoma
- Interventions
- rituximab, clofarabine, DNA methylation analysis, gene expression analysis, microarray analysis, polymerase chain reaction, high performance liquid chromatography, laboratory biomarker analysis
- Biological · Drug · Genetic + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Ischemia-Reperfusion Injury, Lung Transplantation
- Interventions
- Repertaxin, Placebo
- Drug · Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Denver, Colorado • St Louis, Missouri + 2 more
- Conditions
- 1 Fluid Management
- Interventions
- Deltex CardioQ Probe
- Device
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Peripheral Artery Disease
- Interventions
- Contrast Injection, Dextran Injection, CO2 Injection, Heparinized Normal Saline Injection
- Procedure
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Acute Respiratory Failure
- Interventions
- Noninvasive positive pressure ventilation (NIPPV), Vapotherm
- Device
- Lead sponsor
- Vapotherm, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 5
- States / cities
- Athens, Georgia • Florence, South Carolina • Chattanooga, Tennessee + 2 more
- Conditions
- Lymphoma
- Interventions
- rituximab, cyclophosphamide, Doxorubicin, Prednisone, Vincristine
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 153
- States / cities
- Little Rock, Arkansas • Lewes, Delaware • Newark, Delaware + 96 more
- Conditions
- Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- Dexamethasone, Floxuridine, Implanted Medical Device, Irinotecan, Leucovorin, Oxaliplatin, Quality-of-Life Assessment
- Drug · Device · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Asthma, Copd, Acute Exacerbation of COPD
- Interventions
- Inhaler Trainer System, Initial Inhaler Use Assessment, Inhaler Use Instruction
- Device · Other
- Lead sponsor
- Koronis Biomedical Technologies
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Bladder Outlet Obstruction, Lower Urinary Tract Symptoms
- Interventions
- Disposable device, Digital device, Clinic flow measurement
- Device
- Lead sponsor
- Wellspect HealthCare
- Industry
- Eligibility
- 45 Years to 85 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Nocturnal Enuresis
- Interventions
- PureWick™ System, Hollister® Female Urinary Pouch External Collection Device
- Device
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Dunwoody, Georgia • New York, New York
- Conditions
- Acute Leukemia, Myelodysplasia
- Interventions
- Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate
- Procedure · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 1 Year to 65 Years
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 28
- States / cities
- Duarte, California • Stanford, California • Gainesville, Florida + 22 more
- Conditions
- Asthma, Asthma Attack, Asthma, Allergic
- Interventions
- Spirobank Smart spirometer
- Device
- Lead sponsor
- VitalFlo Inc.
- Industry
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Raleigh, North Carolina
- Conditions
- Acute Lung Injury, Adult Respiratory Distress Syndrome, Kidney Injury
- Interventions
- Volume-Cycled Assist-Control (AC) mode, Airway Pressure Release Ventilation (APRV) mode
- Device
- Lead sponsor
- University of Tennessee, Chattanooga
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Chattanooga, Tennessee
- Conditions
- Brain Tumors
- Interventions
- Induction therapy (Regimen 1, Course 1, Cycle A1, Regimen 1, Course 1, Cycle A2 (Days 22 - 42), Cycle B, Regimen 1, Course 2, Intrathecal Mafosfamide, Regimen 1 Course 2, IT mafosfamide, Regimen 2, Course 1, Regimen 2, Course, 1, Cycle C1, Regimen 2, Course 2, radiation therapy
- Drug · Radiation
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 36 Months
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 3
- States / cities
- Durham, North Carolina • Memphis, Tennessee • Houston, Texas
- Conditions
- Chronic Fatigue Syndrome, Fibromyalgia
- Interventions
- A Peltier for Sensory testing, functional magnetic resonance imaging for Brain Neuroimaging, fMRI for Spinal Cord Neuroimaging
- Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Pain
- Interventions
- Ropivacaine 0.1%, Ropivacaine 0.2%, Normal saline, On-Q ® elastomeric pump
- Drug · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Down Syndrome
- Interventions
- Hand grip exercise and lower body negative pressure
- Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Respiratory Failure, Dyspnea During Mechanical Ventilation, Mechanical Ventilation
- Interventions
- Change to VC/AC, Change in Tidal Volume, Change in inspiratory flow, Change in PEEP, Change to PSV
- Other
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Down Syndrome
- Interventions
- Combined exercise intervention, Usual care / Sham intervention
- Behavioral
- Lead sponsor
- University of Nevada, Las Vegas
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Atrial Fibrillation (AF), Atrial Flutter
- Interventions
- Cardiac computed tomography angiography, Standard of care management
- Diagnostic Test · Other
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Liver Cancer
- Interventions
- bevacizumab, dexamethasone, floxuridine, protein expression analysis, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2024
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Pancreatic Cancer
- Interventions
- Lidocaine Hydrochloride, Saline Solution for Injection
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois